scholarly journals A Soft Voting Ensemble-Based Model for the Early Prediction of Idiopathic Pulmonary Fibrosis (IPF) Disease Severity in Lungs Disease Patients

Life ◽  
2021 ◽  
Vol 11 (10) ◽  
pp. 1092
Author(s):  
Sikandar Ali ◽  
Ali Hussain ◽  
Satyabrata Aich ◽  
Moo Suk Park ◽  
Man Pyo Chung ◽  
...  
Keyword(s):  
Machine Learning ◽  
Idiopathic Pulmonary Fibrosis ◽  
Pulmonary Fibrosis ◽  
Lung Disease ◽  
Lung Diseases ◽  
Early Stage ◽  
Confusion Matrix ◽  
Machine Learning Techniques ◽  
Training Dataset ◽  
Proposed Model

Idiopathic pulmonary fibrosis, which is one of the lung diseases, is quite rare but fatal in nature. The disease is progressive, and detection of severity takes a long time as well as being quite tedious. With the advent of intelligent machine learning techniques, and also the effectiveness of these techniques, it was possible to detect many lung diseases. So, in this paper, we have proposed a model that could be able to detect the severity of IPF at the early stage so that fatal situations can be controlled. For the development of this model, we used the IPF dataset of the Korean interstitial lung disease cohort data. First, we preprocessed the data while applying different preprocessing techniques and selected 26 highly relevant features from a total of 502 features for 2424 subjects. Second, we split the data into 80% training and 20% testing sets and applied oversampling on the training dataset. Third, we trained three state-of-the-art machine learning models and combined the results to develop a new soft voting ensemble-based model for the prediction of severity of IPF disease in patients with this chronic lung disease. Hyperparameter tuning was also performed to get the optimal performance of the model. Fourth, the performance of the proposed model was evaluated by calculating the accuracy, AUC, confusion matrix, precision, recall, and F1-score. Lastly, our proposed soft voting ensemble-based model achieved the accuracy of 0.7100, precision 0.6400, recall 0.7100, and F1-scores 0.6600. This proposed model will help the doctors, IPF patients, and physicians to diagnose the severity of the IPF disease in its early stages and assist them to take proactive measures to overcome this disease by enabling the doctors to take necessary decisions pertaining to the treatment of IPF disease.

scholarly journals Antifibrotic Therapies and Progressive Fibrosing Interstitial Lung Disease (PF-ILD): Building on INBUILD

2021 ◽  
Vol 10 (11) ◽  
pp. 2285
Author(s):  
John N. Shumar ◽  
Abhimanyu Chandel ◽  
Christopher S. King
Keyword(s):  
Interstitial Lung Disease ◽  
Idiopathic Pulmonary Fibrosis ◽  
Pulmonary Fibrosis ◽  
Lung Disease ◽  
Lung Diseases ◽  
Interstitial Lung Diseases ◽  
Treatment Pathway ◽  
Antifibrotic Therapy ◽  
New Treatment ◽  
Fibrotic Lung Diseases

Progressive fibrosing interstitial lung disease (PF-ILD) describes a phenotypic subset of interstitial lung diseases characterized by progressive, intractable lung fibrosis. PF-ILD is separate from, but has radiographic, histopathologic, and clinical similarities to idiopathic pulmonary fibrosis. Two antifibrotic medications, nintedanib and pirfenidone, have been approved for use in patients with idiopathic pulmonary fibrosis. Recently completed randomized controlled trials have demonstrated the clinical efficacy of antifibrotic therapy in patients with PF-ILD. The validation of efficacy of antifibrotic therapy in PF-ILD has changed the treatment landscape for all of the fibrotic lung diseases, providing a new treatment pathway and opening the door for combined antifibrotic and immunosuppressant drug therapy to address both the fibrotic and inflammatory components of ILD characterized by mixed pathophysiologic pathways.

scholarly journals Comparison of Characteristics of Connective Tissue Disease-Associated Interstitial Lung Diseases, Undifferentiated Connective Tissue Disease-Associated Interstitial Lung Diseases, and Idiopathic Pulmonary Fibrosis in Chinese Han Population: A Retrospective Study

2013 ◽  
Vol 2013 ◽  
pp. 1-7 ◽  
Author(s):  
Lin Pan ◽  
Yuan Liu ◽  
Rongfei Sun ◽  
Mingyu Fan ◽  
Guixiu Shi
Keyword(s):  
Interstitial Lung Disease ◽  
Idiopathic Pulmonary Fibrosis ◽  
Connective Tissue ◽  
Pulmonary Fibrosis ◽  
Lung Disease ◽  
Connective Tissue Disease ◽  
Lung Diseases ◽  
Interstitial Lung Diseases ◽  
Western China ◽  
Undifferentiated Connective Tissue Disease

Our study compared the prevalence and characteristics of patients with connective tissue disease-associated interstitial lung disease (CTD-ILD), undifferentiated connective tissue disease-associated interstitial lung disease (UCTD-ILD), or idiopathic pulmonary fibrosis (IPF) between January 2009 and December 2012 in West China Hospital, western China. Patients who met the criteria for ILD were included and were assigned to CTD-ILD, UCTD-ILD, or IPF group when they met the criteria for CTD, UCTD, or IPF, respectively. Clinical characteristics, laboratory tests, and high-resolution CT images were analyzed and compared among three groups. 203 patients were included, and all were Han nationality. CTD-ILD was identified in 31%, UCTD-ILD in 32%, and IPF in 37%. Gender and age differed among groups. Pulmonary symptoms were more common in IPF, while extrapulmonary symptoms were more common in CTD-ILD and UCTD-ILD group. Patients with CTD-ILD had more abnormal antibody tests than those of UCTD-ILD and IPF. Little significance was seen in HRCT images among three groups. A systematic evaluation of symptoms and serologic tests in patients with ILD can identify CTD-ILD, UCTD-ILD, and IPF.

Idiopathic Lung Diseases Other than Pulmonary Fibrosis

2017 ◽  
Author(s):  
Lawrence A Ho ◽  
Bridget F Collins ◽  
Ganesh Raghu
Keyword(s):  
Idiopathic Pulmonary Fibrosis ◽  
Pulmonary Fibrosis ◽  
Lung Disease ◽  
Lung Diseases ◽  
Vascular Diseases ◽  
Basement Membranes ◽  
European Respiratory Society ◽  
Drug Induced ◽  
Collagen Vascular Diseases ◽  
Diffuse Parenchymal Lung Diseases

Idiopathic lung diseases are diffuse parenchymal lung diseases that are grouped under the term interstitial lung disease (ILD). The term interstitial (or interstitium) is, however, misleading as the term interstitium refers to the microscopic anatomic space between the basement membranes of the endothelial and epithelial cells. The pathologic processes involved in these diseases, however, are not limited to the interstitium and can affect other elements of the gas exchange units as well as bronchiolar lumen, terminal bronchioles, pulmonary parenchyma, and pleural and vascular spaces. Since there are potentially hundreds of agents and clinical situations that are associated with ILD, a simplified grouping scheme includes seven main entities: ILD associated with (1) occupational and environmental factors (inhalation cause), (2) collagen vascular diseases, (3) granulomatous lung disease of known and unknown causes (eg, hypersensitivity pneumonitis [HP], sarcoidosis), (4) inherited diseases, (5) iatrogenic/drug induced, (6) certain specific entities (eg, pulmonary Langerhans cell histiocytosis [PLCH], lymphangioleimyomatosis, and (7) idiopathic interstitial pneumonia (IIP). As idiopathic pulmonary fibrosis (IPF) is a subgroup of IIP, this review focuses on the clinical features and management of the major IIPs, and IPF is discussed more in the review, “Idiopathic Pulmonary Fibrosis,” found elsewhere in this publication. This review also focuses on HP as it is a key disease in the differential diagnosis of the IIPs. Figures depict chest radiographs, high resolution computed topography (HRCT) scans, and histopathologic features of various ILDs. Tables list the American Thoracic Society (ATS) and the European Respiratory Society (ERS) classification of IIPs, and common antigens associated with HP and their potential sources. This review contains 22 highly rendered figures, 2 tables, and 156 references.

Chronic fibrosing progressing interstitial lung disease: a decision of Multidisciplinary Expert Board

2021 ◽  
Vol 31 (4) ◽  
pp. 505-510
Author(s):  
S. N. Avdeev ◽  
S. Yu. Chikina ◽  
I. E. Tyurin ◽  
A. S. Belevskiy ◽  
S. A. Terpigorev ◽  
...  
Keyword(s):  
Interstitial Lung Disease ◽  
Lung Function ◽  
Idiopathic Pulmonary Fibrosis ◽  
Pulmonary Fibrosis ◽  
Lung Disease ◽  
Russian Federation ◽  
Lung Diseases ◽  
Interstitial Lung Diseases ◽  
Diagnosis And Treatment ◽  
Antifibrotic Therapy

Introduction. The natural course of some interstitial lung diseases (ILD) is characterized by progressive fibrosing phenotype resembling idiopathic pulmonary fibrosis (IPF). Until recently, the antifibrotic drug nintedanib was approved for treatment of the only fibrosing ILD which was IPF. A new indication for this drug which has been registered in Russian Federation in 2021 includes other fibrosing ILDs with progressive phenotype (PF-ILDs) and ILD associated with systemic scleroderma (SS-ILD).The aim of this publication is to describe general considerations of the decision of Multidisciplinary Expert Board on diagnosis and treatment of PF-ILDs including SS-ILD.Results. According to the extension in nintedanib use mentioned above, the Expert Board created an algorithm for diagnosis and treatment of patients with PF-ILDs and criteria for nuntedanib administration in PF-ILDs.Conclusion. Antifibrotic therapy is needed for patients with PF-ILDs with the failure of the stanrard therapy. In those patients antifibrotic treatment should be initiated as early as possible to better preserve the lung function.

scholarly journals Deep learning in interstitial lung disease—how long until daily practice

2020 ◽  
Vol 30 (11) ◽  
pp. 6285-6292
Author(s):  
Ana Adriana Trusculescu ◽  
Diana Manolescu ◽  
Emanuela Tudorache ◽  
Cristian Oancea
Keyword(s):  
Deep Learning ◽  
Idiopathic Pulmonary Fibrosis ◽  
Pulmonary Fibrosis ◽  
Early Diagnosis ◽  
Lung Disease ◽  
Lung Diseases ◽  
Daily Practice ◽  
Interstitial Lung Diseases ◽  
Learning Approaches ◽  
High Resolution Computed Tomography

Abstract Interstitial lung diseases are a diverse group of disorders that involve inflammation and fibrosis of interstitium, with clinical, radiological, and pathological overlapping features. These are an important cause of morbidity and mortality among lung diseases. This review describes computer-aided diagnosis systems centered on deep learning approaches that improve the diagnostic of interstitial lung diseases. We highlighted the challenges and the implementation of important daily practice, especially in the early diagnosis of idiopathic pulmonary fibrosis (IPF). Developing a convolutional neuronal network (CNN) that could be deployed on any computer station and be accessible to non-academic centers is the next frontier that needs to be crossed. In the future, early diagnosis of IPF should be possible. CNN might not only spare the human resources but also will reduce the costs spent on all the social and healthcare aspects of this deadly disease. Key Points • Deep learning algorithms are used in pattern recognition of different interstitial lung diseases. • High-resolution computed tomography plays a central role in the diagnosis and in the management of all interstitial lung diseases, especially fibrotic lung disease. • Developing an accessible algorithm that could be deployed on any computer station and be used in non-academic centers is the next frontier in the early diagnosis of idiopathic pulmonary fibrosis.

scholarly journals Management of patients with fibrosing interstitial lung diseases

2021 ◽  
Author(s):  
Lee E Morrow ◽  
Daniel Hilleman ◽  
Mark A Malesker
Keyword(s):  
Interstitial Lung Disease ◽  
Idiopathic Pulmonary Fibrosis ◽  
Pulmonary Fibrosis ◽  
Lung Disease ◽  
Lung Diseases ◽  
Underlying Disease ◽  
Interstitial Lung Diseases ◽  
Interstitial Space ◽  
Fda Approval ◽  
Antifibrotic Agents

Abstract Disclaimer In an effort to expedite the publication of articles, AJHP is posting manuscripts online as soon as possible after acceptance. Accepted manuscripts have been peer-reviewed and copyedited, but are posted online before technical formatting and author proofing. These manuscripts are not the final version of record and will be replaced with the final article (formatted per AJHP style and proofed by the authors) at a later time. Purpose This article summarizes the appropriate use and pharmacology of treatments for fibrosing interstitial lung diseases, with a specific focus on the antifibrotic agents nintedanib and pirfenidone. Summary The interstitial lung diseases are a heterogenous group of parenchymal lung disorders with a common feature—infiltration of the interstitial space with derangement of the normal capillary-alveolar anatomy. Diseases characterized by fibrosis of the interstitial space are referred to as the fibrosing interstitial lung diseases and often show progression over time: idiopathic pulmonary fibrosis is the most common fibrotic interstitial lung disease. Historically, therapies for fibrosing lung diseases have been limited in number, questionable in efficacy, and associated with potential harms. Food and Drug Administration (FDA) approval of the antifibrotic agents nintedanib and pirfenidone for idiopathic pulmonary fibrosis in 2014 heralded an era of reorganization of therapy for the fibrotic interstitial lung diseases. Subsequent investigations have led to FDA approval of nintedanib for systemic sclerosis–associated interstitial lung disease and interstitial lung diseases with a progressive phenotype. Although supportive care and pulmonary rehabilitation should be provided to all patients, the role(s) of immunomodulators and/or immune suppressing agents vary by the underlying disease state. Several agents previously used to treat fibrotic lung diseases (N-acetylcysteine, anticoagulation, pulmonary vasodilators) lack efficacy or cause harm. Conclusion With the introduction of effective pharmacotherapy for fibrosing interstitial lung disease, pharmacists have an increasingly important role in the interdisciplinary team managing these patients.

Idiopathic Lung Diseases Other than Pulmonary Fibrosis

2017 ◽  
Author(s):  
Lawrence A Ho ◽  
Bridget F Collins ◽  
Ganesh Raghu
Keyword(s):  
Idiopathic Pulmonary Fibrosis ◽  
Pulmonary Fibrosis ◽  
Lung Disease ◽  
Lung Diseases ◽  
Vascular Diseases ◽  
Basement Membranes ◽  
European Respiratory Society ◽  
Drug Induced ◽  
Collagen Vascular Diseases ◽  
Diffuse Parenchymal Lung Diseases

Idiopathic lung diseases are diffuse parenchymal lung diseases that are grouped under the term interstitial lung disease (ILD). The term interstitial (or interstitium) is, however, misleading as the term interstitium refers to the microscopic anatomic space between the basement membranes of the endothelial and epithelial cells. The pathologic processes involved in these diseases, however, are not limited to the interstitium and can affect other elements of the gas exchange units as well as bronchiolar lumen, terminal bronchioles, pulmonary parenchyma, and pleural and vascular spaces. Since there are potentially hundreds of agents and clinical situations that are associated with ILD, a simplified grouping scheme includes seven main entities: ILD associated with (1) occupational and environmental factors (inhalation cause), (2) collagen vascular diseases, (3) granulomatous lung disease of known and unknown causes (eg, hypersensitivity pneumonitis [HP], sarcoidosis), (4) inherited diseases, (5) iatrogenic/drug induced, (6) certain specific entities (eg, pulmonary Langerhans cell histiocytosis [PLCH], lymphangioleimyomatosis, and (7) idiopathic interstitial pneumonia (IIP). As idiopathic pulmonary fibrosis (IPF) is a subgroup of IIP, this review focuses on the clinical features and management of the major IIPs, and IPF is discussed more in the review, “Idiopathic Pulmonary Fibrosis,” found elsewhere in this publication. This review also focuses on HP as it is a key disease in the differential diagnosis of the IIPs. Figures depict chest radiographs, high resolution computed topography (HRCT) scans, and histopathologic features of various ILDs. Tables list the American Thoracic Society (ATS) and the European Respiratory Society (ERS) classification of IIPs, and common antigens associated with HP and their potential sources. This review contains 22 highly rendered figures, 2 tables, and 156 references.

Idiopathic pulmonary fibrosis

2017 ◽  
Author(s):  
Clare Ross ◽  
Athol Wells
Keyword(s):  
Interstitial Lung Disease ◽  
Idiopathic Pulmonary Fibrosis ◽  
Connective Tissue ◽  
Pulmonary Fibrosis ◽  
Lung Disease ◽  
Lung Diseases ◽  
Interstitial Lung Diseases ◽  
Heterogeneous Group

Interstitial lung diseases are a complex heterogeneous group which are challenging to diagnose and treat. The diagnosis of idiopathic pulmonary fibrosis, as opposed to connective tissue interstitial lung disease, is important, as treatments and prognoses are very different. This chapter focusses on a case where this diagnosis is challenging. The evidence for the treatment of idiopathic pulmonary fibrosis is reviewed, in light of recent trials and new recommendations.

Sign in / Sign up

Export Citation Format

Share Document